David Groff

Nov 8, 2023 | nature.com | Quinlen Marshall |John Warrington |Alvin Farrel |David Groff |Sarvind Tripathi |Son Nguyen | +3 more

AbstractThe majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes1. However, most cancers have a modest mutational burden that is insufficient for generating responses using neoantigen-based therapies2,3. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcriptional networks4.